Call the Mercy Medical Research Institute at (417)841-0250 or toll-free 1-866-207-0167 (for those outside the 417 area code) if you are interested in participating in a clinical trial. You may also want to contact your physician for more information before participating.
Phase III Randomized, Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer.
Vicki Canfield, M.D.
A randomized phase III clinical trial evaluating post-mastectomy chestwall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy
Astrid Morrison, M.D.
A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2 + Metastatic breast cancer who have received two prior anti-HER2 therapies and require systemic treatment
Suzanne Cole, M.D.
MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of post menopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no prior endocrine treatment or only one line of prior endocrine treatment
James Reeves, M.D.